Bio-Rad Announces Receipt of New Ruling in Applied Biosystems Patent Infringement Dispute
2005年11月23日 - 6:00AM
PRニュース・ワイアー (英語)
HERCULES, Calif., Nov. 22 /PRNewswire-FirstCall/ -- Bio-Rad
Laboratories, Inc. (AMEX: BIO; BIOb), a multinational manufacturer
and distributor of life science research products and clinical
diagnostics, announced today that it is in receipt of a recommended
ruling issued by the U.S. District Court for the District of
Connecticut regarding the longstanding patent infringement dispute
filed by Applera, on behalf of its Applied Biosystems group (ABI),
against MJ Research, Inc. and the outstanding judgment against MJ
Research. The Court has denied MJ Research's motion to enforce a
settlement agreement established on August 29, 2005 among the
parties. MJ Research and Bio-Rad plan to appeal this decision. In
the interim, the company will continue to comply with the
injunction issued by the Court on August 30, 2005. This action is
part of a patent infringement law suit relating to Polymerase Chain
Reaction (PCR) and instruments (thermal cycler) for performing PCR.
While Bio-Rad is a longtime licensee of certain intellectual
property covered by Applera's patents, the company inherited
responsibility for the 1998 patent infringement case brought
against MJ Research as part of its August 2004 acquisition of MJ
GeneWorks, Inc., the parent company of MJ Research. Bio-Rad
Laboratories, Inc. (http://www.bio-rad.com/) is a multinational
manufacturer and distributor of life science research products and
clinical diagnostics. It is based in Hercules, California, and
serves thousands of research and industry customers worldwide
through a network of more than 30 wholly owned subsidiary offices.
Various statements made within this press release may constitute
"forward-looking statements" for purposes of the Securities and
Exchange Commission's "safe harbor" provisions under the Private
Securities Litigation Reform Act of 1995 and Rule 3b-6 under the
Securities Exchange Act of 1934. The forward-looking statements
contained herein involve risks and uncertainties that could cause
results to differ materially from the Company's expectations.
DATASOURCE: Bio-Rad Laboratories, Inc. CONTACT: Christine Tsingos,
Chief Financial Officer, or Ron Hutton, Treasurer, both of Bio-Rad
Laboratories, Inc., +1-510-724-7000, or Web site:
http://www.bio-rad.com/
Copyright